NasdaqGS - Delayed Quote USD
Kronos Bio, Inc. (KRON)
At close: November 21 at 4:00 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Norbert W. Bischofberger Ph.D. | President, CEO & Director | 912.2k | -- | 1956 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 40k | -- | 1977 |
| Mr. David M. Tanen J.D. | Secretary & Director | 40k | -- | 1971 |
| Dr. Deborah A. Knobelman Ph.D. | COO & CFO | -- | -- | 1974 |
| Dr. Charles Lin Ph.D. | Chief Scientific Officer | -- | -- | 1985 |
| Ms. Allison Frisbee J.D. | Chief Administrative Officer | -- | -- | 1983 |
| Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations | -- | -- | -- |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development | -- | -- | 1965 |
| Mr. Wes Trotter Ph.D. | Senior Vice President of Drug Discovery & Pharmaceutical Development | -- | -- | -- |
Kronos Bio, Inc.
1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 58
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Corporate Governance
Kronos Bio, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 13, 2024 at 9:05 PM UTC
Kronos Bio, Inc. Earnings Date
Recent Events
Related Tickers
AADI Aadi Bioscience, Inc.
2.2800
+2.70%
ACHL Achilles Therapeutics plc
1.0700
0.00%
ASMB Assembly Biosciences, Inc.
14.72
-2.00%
ANTX AN2 Therapeutics, Inc.
1.2300
-5.38%
OKUR OnKure Therapeutics, Inc.
15.99
-0.06%
SEER Seer, Inc.
2.3800
+3.93%
IPSC Century Therapeutics, Inc.
1.2400
-1.59%
GLTO Galecto, Inc.
5.85
-1.60%
NXTC NextCure, Inc.
1.2900
-0.77%
HLVX HilleVax, Inc.
1.8200
+1.68%